AP3583A - Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine - Google Patents

Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Info

Publication number
AP3583A
AP3583A AP2013006768A AP2013006768A AP3583A AP 3583 A AP3583 A AP 3583A AP 2013006768 A AP2013006768 A AP 2013006768A AP 2013006768 A AP2013006768 A AP 2013006768A AP 3583 A AP3583 A AP 3583A
Authority
AP
ARIPO
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
therapeutic uses
Prior art date
Application number
AP2013006768A
Other languages
English (en)
Other versions
AP2013006768A0 (en
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AP2013006768A0 publication Critical patent/AP2013006768A0/xx
Application granted granted Critical
Publication of AP3583A publication Critical patent/AP3583A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2013006768A 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine AP3583A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35788510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (2)

Publication Number Publication Date
AP2013006768A0 AP2013006768A0 (en) 2012-03-31
AP3583A true AP3583A (en) 2016-02-09

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006768A AP3583A (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Country Status (30)

Country Link
US (5) US20130184291A1 (sl)
EP (1) EP2608789B2 (sl)
JP (1) JP5902169B2 (sl)
KR (1) KR101816953B1 (sl)
CN (1) CN103068389A (sl)
AP (1) AP3583A (sl)
AR (1) AR082501A1 (sl)
AU (1) AU2011295465B8 (sl)
BR (2) BR112013002194A2 (sl)
CA (1) CA2807062C (sl)
CL (1) CL2013000492A1 (sl)
CO (1) CO6680652A2 (sl)
CY (1) CY1118886T1 (sl)
DK (1) DK2608789T3 (sl)
ES (1) ES2625142T3 (sl)
HR (1) HRP20170608T1 (sl)
HU (1) HUE034155T2 (sl)
IL (1) IL224371A (sl)
LT (1) LT2608789T (sl)
ME (1) ME02674B (sl)
MX (1) MX349724B (sl)
PL (1) PL2608789T3 (sl)
PT (1) PT2608789T (sl)
RS (1) RS55851B1 (sl)
RU (1) RU2564666C2 (sl)
SG (1) SG187649A1 (sl)
SI (1) SI2608789T1 (sl)
TW (1) TW201212918A (sl)
WO (1) WO2012025123A1 (sl)
ZA (1) ZA201301385B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009062517A1 (en) * 2007-11-13 2009-05-22 H. Lundbeck A/S Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0543584B1 (en) * 1991-11-18 1996-05-22 Lilly Industries Limited Benzo(b)thiophene-2-carboxamides for the treatment of disorders of the central nervous system
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7159383B2 (en) 2000-10-02 2007-01-09 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009062517A1 (en) * 2007-11-13 2009-05-22 H. Lundbeck A/S Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTIGAS, F., ET AL, "A Randomised, double-blind, placebo-controlle, active-referenced study of LuAA21004 in patients with major depression". European Neuropsychopharmacology, 2009, vol. 19, pages S426-S427 *

Also Published As

Publication number Publication date
US20130184291A1 (en) 2013-07-18
PT2608789T (pt) 2017-05-26
IL224371A (en) 2016-07-31
US20220370439A1 (en) 2022-11-24
RS55851B1 (sr) 2017-08-31
BR122020025600A2 (pt) 2021-01-05
KR20130097162A (ko) 2013-09-02
SG187649A1 (en) 2013-03-28
BR112013002194A2 (pt) 2016-05-31
CL2013000492A1 (es) 2013-06-07
AR082501A1 (es) 2012-12-12
JP5902169B2 (ja) 2016-04-13
ZA201301385B (en) 2014-04-30
CY1118886T1 (el) 2018-01-10
RU2564666C2 (ru) 2015-10-10
EP2608789A1 (en) 2013-07-03
CN103068389A (zh) 2013-04-24
ES2625142T3 (es) 2017-07-18
US20210085674A1 (en) 2021-03-25
KR101816953B1 (ko) 2018-01-09
CA2807062C (en) 2018-07-31
CA2807062A1 (en) 2012-03-01
JP2013536206A (ja) 2013-09-19
AP2013006768A0 (en) 2012-03-31
MX349724B (es) 2017-08-10
US20190000836A1 (en) 2019-01-03
DK2608789T3 (en) 2017-05-15
TW201212918A (en) 2012-04-01
AU2011295465B2 (en) 2014-06-19
CO6680652A2 (es) 2013-05-31
AU2011295465B8 (en) 2014-07-10
SI2608789T1 (sl) 2017-06-30
ME02674B (me) 2017-06-20
EP2608789B2 (en) 2024-08-21
WO2012025123A1 (en) 2012-03-01
EP2608789B1 (en) 2017-04-12
RU2013112890A (ru) 2014-09-27
US20240293397A1 (en) 2024-09-05
PL2608789T3 (pl) 2017-09-29
MX2013001570A (es) 2013-03-21
HUE034155T2 (en) 2018-01-29
LT2608789T (lt) 2017-05-25
HRP20170608T1 (hr) 2017-07-28
AU2011295465A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
HK1165955A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)]
IL246600B (en) Heterocyclic compounds and their use
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
PL2521450T3 (pl) Grzybobójcze związki heterocykliczne
IL225770A0 (en) Heterocyclic compounds
EP2637669A4 (en) Heterocyclic compounds and their use
EP2575462A4 (en) Heterocyclic compounds and their use
EP2643000A4 (en) THERAPEUTIC PIPERAZINES
HRP20130819T1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
AP2013006987A0 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
IL223721A0 (en) Heterocyclic compounds, their preparation and their therapeutic application
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
IL213917A0 (en) Novel compounds for medical use as peptidase effectors
HK1178529A1 (en) Piperazines as antimalarial agents
GB201019043D0 (en) Use of 2',5'-oligoadenylate derivative compounds
PL393335A1 (pl) Nowe E-1,2-bis{4-[(2-(1-oxo-alkilo)-3-oxo-alkilo]fenylo) eteny oraz sposób ich otrzymywania
GB201021416D0 (en) Novel heterocyclic compounds
GB201009514D0 (en) Novel heterocyclic compounds
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101821D0 (en) Novel heterocyclic compounds 1
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101822D0 (en) Novel heterocyclic compounds 2